infections, the two estimates of the percentage found in G20 countries and Nigeria are almost the same. Indeed, with the exception of visceral leishmaniasis, the results show a relatively high concurrence between GBD 2013 and WHO or other estimates, in terms of the high percentage of NTDs, HIV/AIDS, TB, and malaria found in G20 countries together with Nigeria. The basis for the different results for visceral leishmaniasis is under investigation, while the fact that the dengue estimates are identical between GBD 2013 and those reported earlier based on studies conducted by Bhatt et al. may reflect their use of similar or identical sources of data [9] .
A further analysis of the NTD DALYs in the blue marble health countries is shown in Fig 4 . It shows that India has the highest disease burden, led by leishmaniasis, followed by China, mostly due to food-borne trematodiases. Nigeria exhibited the third highest NTD burden, followed by Indonesia, Brazil, South Africa, Mexico, Argentina, South Korea, Turkey, and Russia. However, the disease burdens for some blue marble health countries may be underestimated in the GBD 2013. For example, the US has a substantial burden of Chagas disease and cysticercosis that is not represented in the GBD 2013, while for other neglected diseases that are widespread in the US, such as toxoplasmosis and toxocariasis, there are no specific DALYs assigned in either the GBD 2010 or GBD 2013 [8] .
Finally, Fig 5 shows some recent changes in the ranking of the NTDs and malaria in the G20 countries and Nigeria since 1990. Regarding the G20 countries, ascariasis exhibited the greatest drop in rank, possibly due to mass drug administration using anthelminthic drugs, whereas the food-borne trematodiases, visceral leishmaniasis, hookworm, lymphatic filariasis, dengue, Chagas disease, and cysticercosis went up in rank. For Nigeria there appeared to be no major shifts in the rankings since 1990 [8]. In summary, information using DALYs from the GBD 2013 confirms the findings related to blue marble health that were previously derived using WHO and other data. The concurrence provides further impetus for pursuing public policies related to a framework for blue marble health for the G20 countries and Nigeria. Among those policies is greater engagement by G20 government leaders to provide mass drug administration for the major NTDs affecting their vulnerable populations, in addition to preventive measures for HIV/AIDS, TB, and malaria [6] . There is also heightened urgency to increase commitments for neglected diseases research and development (R&D) among the G20 leaders [6] .
